MARKET

ASRT

ASRT

Assertio Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9400
+0.0364
+4.03%
After Hours: 0.9100 -0.03 -3.19% 18:54 09/24 EDT
OPEN
0.9200
PREV CLOSE
0.9036
HIGH
0.9400
LOW
0.9081
VOLUME
295.10K
TURNOVER
--
52 WEEK HIGH
5.80
52 WEEK LOW
0.8700
MARKET CAP
41.82M
P/E (TTM)
-0.6893
1D
5D
1M
3M
1Y
5Y
Bausch to pay $300 mln in antitrust suit over diabetes drug
reuters.com · 09/09 21:56
New Strong Sell Stocks for September 9th
Zacks.com · 09/09 14:10
New Strong Sell Stocks for September 7th
Zacks.com · 09/07 13:19
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
ASRT, GOCO, AEYE among mid-day movers
Gainers: NanoVibronix (NASDAQ:NAOV) +47%. Enlivex Therapeutics (NASDAQ:ENLV) +20%. GoHealth (NASDAQ:GOCO) +16%. Travere Therapeutics (NASDAQ:TVTX) +16%. Collegium Pharmaceutical (NASDAQ:COLL) +16%. Auddia (NASDAQ:AUUD) +15%. AudioEye (NASDAQ:AEYE) +14%. Co...
Seekingalpha · 08/16 16:38
BRIEF-Assertio Holdings QTRLY Loss Per Share $0.32
reuters.com · 08/05 20:47
Assertio Therapeutics EPS misses by $0.24, beats on revenue; raises full year guidance
Assertio Therapeutics (NASDAQ:ASRT): Q2 GAAP EPS of -$0.32 misses by $0.24. Revenue of $25.37M (+23.0% Y/Y) beats by $4.99M. FY21 guidance: GAAP net product sales is seen in the range
Seekingalpha · 08/05 20:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ASRT. Analyze the recent business situations of Assertio Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ASRT stock price target is 6.20 with a high estimate of 6.20 and a low estimate of 6.20.
EPS
Institutional Holdings
Institutions: 177
Institutional Holdings: 11.56M
% Owned: 25.97%
Shares Outstanding: 44.49M
TypeInstitutionsShares
Increased
10
1.84M
New
4
339.46K
Decreased
21
707.73K
Sold Out
19
2.64M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Peter Staple
President/Chief Executive Officer/Director
Daniel Peisert
Chief Financial Officer/Senior Vice President
Paul Schwichtenberg
Senior Vice President/Chief Accounting Officer
Ajay Patel
Independent Director
Heather Mason
Independent Director
William Mckee
Independent Director
James Tyree
No Data
  • All
  • Financials
  • Insiders
More
About ASRT
Assertio Holdings, Inc. is a specialty pharmaceutical company. The Company owns a portfolio of prescription neurology, inflammation and pain medications. Its marketed products include Cambia (diclofenac potassium) for Oral solution, INDOCIN Oral Suspension, INDOCIN (indomethacin) Suppositories, OXAYDO tablets, SPRIX Nasal Spray, VIVLODEX capsules, ZIPSOR Liquid filled capsules and ZORVOLEX capsules. The Company is also focused on developing and commercializing neurology, orphan and specialty medicines. Its pipeline products include Diclofenac Potassium, Long-acting Cosyntropin and Diclofenac potassium. Diclofenac Potassium is being developed for mild/moderate acute pain. Long-acting Cosyntropin is being developed for diagnosis of adrenal insufficiency. Diclofenac potassium is a liquid formulation being developed for acute migraine attacks.

Webull offers kinds of Assertio Holdings Inc stock information, including NASDAQ:ASRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASRT stock methods without spending real money on the virtual paper trading platform.